sameAs
P3781
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral RegimenPharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects
P921
description
drug combination for HIV
@en
name
Abacavir/dolutegravir/lamivudine
@en
Abacavir/dolutegravir/lamivudine
@nl
Triumeq
@es
أباكافير/دولوتغرافير/لاميفودين
@ar
綏美凱
@zh-hant
绥美凯
@zh-hans
阿巴卡維/度魯特韋/拉米夫定
@zh
type
label
Abacavir/dolutegravir/lamivudine
@en
Abacavir/dolutegravir/lamivudine
@nl
Triumeq
@es
أباكافير/دولوتغرافير/لاميفودين
@ar
綏美凱
@zh-hant
绥美凯
@zh-hans
阿巴卡維/度魯特韋/拉米夫定
@zh
altLabel
abacavir / dolutegravir / Lamivudine
@en
abacavir sulfate / dolutegravir sodium / lamivudine
@en
绥美凯
@zh
prefLabel
Abacavir/dolutegravir/lamivudine
@en
Abacavir/dolutegravir/lamivudine
@nl
Triumeq
@es
أباكافير/دولوتغرافير/لاميفودين
@ar
綏美凱
@zh-hant
绥美凯
@zh-hans
阿巴卡維/度魯特韋/拉米夫定
@zh
P31
P527
P6366
P662
P2017
C[C@@H]1CCO[C@@H]2N1C(=O)C3=C( ...... ](O[C@H](S1)CO)N2C=CC(=NC2=O)N
P2067
934.335599
P233
CC1CCOC2N1C(=O)C3=C(C(=O)C(=CN ...... N.C1C(OC(S1)CO)N2C=CC(=NC2=O)N
P234
1S/C20H19F2N3O5.C14H18N6O.C8H1 ...... /t10-,15+;8-,10+;6-,7+/m110/s1
P235
SRMOJRAUYXTFJA-RAKRLELNSA-N
P267
P274
C₄₂H₄₈F₂N₁₂O₉S
P3345
P3780
P6366
2776534474